Blanket Purchase Agreement 36F79720D0104-36E79720A0008
Award Date
4/24/20
Last Date to Order
4/23/25
Federal Agency
National Acquisition Center
Awardee
United Therapeutics Corp
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The U.S. Department of Veterans Affairs (VA) has awarded a $198 million Federal Supply Schedule (FSS) contract and a $50 million Blanket Purchase Agreement (BPA) to United Therapeutics Corporation, a self-certified small disadvantaged business and manufacturer of pharmaceutical goods. These Indefinite Delivery Vehicles (IDVs) allow the VA to efficiently procure United Therapeutics' specialized drug portfolio, including treatments for pulmonary arterial hypertension and certain types of cancer,...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to United Therapeutics Corporation, a self-certified small disadvantaged business and for-profit manufacturer of pharmaceutical goods. The BPA has a ceiling value of $207,127,385 and a performance period extending through April 2026. It allows the VA to procure specialized pharmaceutical products from United Therapeutics' portfolio, including Orenitram, Remodulin, Tyvaso,...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to United Therapeutics Corporation. The BPA utilizes the Pharmaceuticals and Drugs GSA Schedule to provide Orentiram, Remodulin, Tyvaso, and Unituxin for an estimated $60 million over a base year and four option years. The BPA aims to procure pharmaceutical products for treatment of pulmonary arterial hypertension and neuroblastoma. Orentiram, Remodulin, and Tyvaso are medications...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer, to provide critical medications for the treatment of rare diseases such as pulmonary arterial hypertension. The $118.5 million BPA covers the period from August 2024 to August 2025 and allows the VA, Federal Bureau of Prisons, and other federal agencies to procure specialized drug therapies like...
Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer, holds a $219,108,390 Federal Supply Schedule (FSS-61-IB) contract with the Department of Veterans Affairs (VA) and two Blanket Purchase Agreements (BPAs) valued at $118.5 million and $83.5 million. These Indefinite Delivery Vehicles (IDVs) enable the VA, Federal Bureau of Prisons, and other federal agencies to efficiently procure specialized pharmaceutical products, particularly treatments for rare diseases like pulmonary...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center of the U.S. Department of Veterans Affairs (VA) to Urogen Pharma Inc., a pharmaceutical company specializing in the drug JELMYTO. The single-award BPA, valued at up to $2.5 million, was made under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and is valid through February 2026. The purpose of this BPA is to provide the VA with a streamlined procurement vehicle to order JELMYTO, a drug used to...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Nobelpharma America, LLC, a foreign-owned, self-certified small disadvantaged business. The single-award BPA, valued at up to $4.5 million, is for the delivery of the medication HYFTOR through June 2026. HYFTOR is likely used to treat conditions like post-traumatic stress disorder and chronic pain among veterans. In addition to this BPA, Nobelpharma America, LLC...
This Blanket Purchase Agreement (BPA) was awarded by the Veterans Integrated Service Network 1 (VISN 1), a division of the U.S. Department of Veterans Affairs (VA), to United Drug Supply Inc., a woman-owned small business located in Morrisville, North Carolina. The single-award BPA, valued at $1, has an ultimate completion date of April 14, 2026, and was awarded on April 15, 2021. The purpose of this BPA is to establish a MEDICAL SURGICAL PRIME VENDOR (MSPV) master agreement, under which...
The U.S. Department of Veterans Affairs (VA) awarded a $3.7 million Blanket Purchase Agreement (BPA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a large pharmaceutical manufacturer. The BPA allows VA medical facilities to place firm fixed price call orders for the oncology medications BALVERSA (erdafitinib) and Belzutifan (WELIREG) through July 2024. This streamlined procurement vehicle supports the VA's Veterans Health Administration (VHA) in maintaining a steady...
The provided information describes a Federal Supply Schedule (FSS) contract awarded by the U.S. Department of Veterans Affairs (VA) to United Drug Supply Inc., a woman-owned small business located in Morrisville, North Carolina. The multiple-award contract, valued at $30,800,000, is for the delivery of drugs, pharmaceuticals, and hematology-related products under Schedule 65 I B. The contract has a performance period from December 2023 to November 2029, enabling United Drug Supply Inc. to...